Delrieu J - Search Results

1

Plasma MCP-1 and changes on cognitive function in community-dwelling older adults.

Sanchez-Sanchez JL, Giudici KV, Guyonnet S, Delrieu J, Li Y, Bateman RJ, Parini A, Vellas B, de Souto Barreto P; MAPT/DSA Group. Sanchez-Sanchez JL, et al. Among authors: delrieu j. Alzheimers Res Ther. 2022 Jan 7;14(1):5. doi: 10.1186/s13195-021-00940-2. Alzheimers Res Ther. 2022. PMID: 34996522 Free PMC article. Clinical Trial.

2

Mild Alzheimer's disease: a "position paper".

Delrieu J, Voisin T, Andrieu S, Belliard S, Belmin J, Blanchard F, Ceccaldi M, Dartigues JF, Defontaines B, Lehericy S, Mekies C, Moreaud O, Naccache L, Nourhashemi F, Ousset PJ, Pasquier F, Payoux P, Puisieux F, Robert P, Touchon J, Vellas B, Dubois B. Delrieu J, et al. J Nutr Health Aging. 2009 Jun;13(6):503-19. doi: 10.1007/s12603-009-0101-2. J Nutr Health Aging. 2009. PMID: 19536419 Free article.

3

Biomarkers in Alzheimer's disease: not yet surrogate endpoints.

Coley N, Andrieu S, Delrieu J, Voisin T, Vellas B. Coley N, et al. Among authors: delrieu j. Ann N Y Acad Sci. 2009 Oct;1180:119-24. doi: 10.1111/j.1749-6632.2009.04947.x. Ann N Y Acad Sci. 2009. PMID: 19906266

4

Sensory alien hand syndrome in corticobasal degeneration: a cerebral blood flow study.

Delrieu J, Payoux P, Toulza O, Esquerre JP, Vellas B, Voisin T. Delrieu J, et al. Mov Disord. 2010 Jul 15;25(9):1288-91. doi: 10.1002/mds.23064. Mov Disord. 2010. PMID: 20589869

5

[The Alzheimer's disease: how to estimate the impact of the pathology and the treatment?].

Delrieu J, Vellas B. Delrieu J, et al. Therapie. 2010 Sep-Oct;65(5):423-8. doi: 10.2515/therapie/2010057. Epub 2010 Dec 13. Therapie. 2010. PMID: 21144477 French.

6

Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.

Delrieu J, Piau A, Caillaud C, Voisin T, Vellas B. Delrieu J, et al. CNS Drugs. 2011 Mar;25(3):213-26. doi: 10.2165/11539810-000000000-00000. CNS Drugs. 2011. PMID: 21323393 Review.

7

[Therapeutic approaches targeting the presumed underlying pathogenic mechanisms in Alzheimer's disease].

Delrieu J, Piau A, Vellas B. Delrieu J, et al. Rev Med Interne. 2011 Jun;32 Suppl 1:S22-5. doi: 10.1016/j.revmed.2011.03.005. Epub 2011 Apr 13. Rev Med Interne. 2011. PMID: 21492970 Review. French. No abstract available.

8

'Clinical trials in Alzheimer's disease': immunotherapy approaches.

Delrieu J, Ousset PJ, Caillaud C, Vellas B. Delrieu J, et al. J Neurochem. 2012 Jan;120 Suppl 1:186-193. doi: 10.1111/j.1471-4159.2011.07458.x. Epub 2011 Nov 28. J Neurochem. 2012. PMID: 21883222 Free article. Retracted. Review.

9

Gantenerumab for the treatment of Alzheimer's disease.

Delrieu J, Ousset PJ, Vellas B. Delrieu J, et al. Expert Opin Biol Ther. 2012 Aug;12(8):1077-86. doi: 10.1517/14712598.2012.688022. Epub 2012 May 15. Expert Opin Biol Ther. 2012. PMID: 22583155 Retracted. Review.

10

Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?

Ousset PJ, Delrieu J, Vellas B. Ousset PJ, et al. Among authors: delrieu j. Alzheimers Res Ther. 2013 Dec 11;5(6):62. doi: 10.1186/alzrt228. eCollection 2013. Alzheimers Res Ther. 2013. PMID: 24325910 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

126 results

Search Page